Joseph Shulman (RYTM) sold 3,984 shares under 10b5-1 plan
Rhea-AI Filing Summary
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals (RYTM), exercised 3,984 stock options with an exercise price of $6.80 per share and immediately sold those 3,984 shares at a weighted average price of $90.0832 on 08/11/2025. The sale was effected pursuant to a Rule 10b5-1 trading instruction adopted on 08/08/2024.
After these transactions, Shulman's reported direct beneficial ownership of common stock declined from 12,493 shares to 8,509 shares. The Form 4 also reports 7,969 stock options outstanding following the transactions.
Positive
- Sale executed under a Rule 10b5-1 plan adopted on 08/08/2024, indicating prearranged trading
- Options exercised at $6.80 per share and sold at a weighted average $90.0832, both prices disclosed
- Disclosure shows remaining options of 7,969, providing visibility into ongoing incentive holdings
Negative
- Direct beneficial ownership decreased from 12,493 shares to 8,509
- Form does not state the use of proceeds from the sale or any secondary transactions beyond the disclosed sale
Insights
TL;DR: Insider exercised options at $6.80 and sold 3,984 shares under a prearranged 10b5-1 plan at a weighted average $90.0832; holdings fell.
The transaction combines an option exercise and an immediate sale, which is common when an executive monetizes vested option tranches. The sale was executed under a documented 10b5-1 plan, reducing signaling risk associated with opportunistic timing. Reported holdings decreased from 12,493 to 8,509 shares, while 7,969 options remain outstanding. This is a routine liquidity event rather than a corporate operational disclosure and appears neutral for near-term fundamentals.
TL;DR: Transaction follows a pre-established 10b5-1 plan and reflects routine insider liquidity rather than an unscheduled disposition.
The Form 4 clearly states the sale was effected pursuant to a Rule 10b5-1 instruction adopted 08/08/2024, indicating pre-planned execution. The combination of option exercise (exercise price $6.80) and immediate sale at a weighted average $90.0832 is consistent with structured exercise-and-sell programs. From a governance perspective, the timely disclosure and use of a 10b5-1 plan indicate adherence to insider-trading controls; the filing does not reveal any corporate governance issues or material noncompliance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 3,984 | $0.00 | -- |
| Exercise | Common Stock | 3,984 | $6.80 | $27K |
| Sale | Common Stock | 3,984 | $90.0832 | $359K |
Footnotes (1)
- The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $90.00 to $90.27 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
